Dutch Patent Act 2026: What Chemical & Biotech Patentees in the Netherlands Must Know

The Dutch Patent Act 2026 is set to reshape how chemical and biotech innovators protect inventions in the Netherlands, marking the most significant overhaul of the national patent system in decades. At its core, the Dutch patent reform reintroduces substantive examination, creating an “examined patent” with materially higher thresholds for novelty and inventive step, while simultaneously opening the door to direct PCT national-phase entry. For R&D managers, in-house counsel and patent strategists in the chemical, food-technology and industrial biotechnology sectors, understanding the Dutch Patent Act 2026 impact in the Netherlands is no longer optional: it directly affects prosecution budgets, claim-drafting methodology, enforcement credibility and portfolio architecture.

This practical guide walks through every decision you need to make, from choosing between examined and unexamined routes to adjusting claim language for a stricter examination regime.

Last updated: 30 April 2026

Executive Summary, TL;DR for Busy Decision-Makers

If you have five minutes, here is what matters most about the Dutch Patent Act 2026 impact in the Netherlands for chemical and biotech patentees:

• Examined patents are back. The Netherlands is reintroducing substantive examination, meaning applicants can, and in certain circumstances must, have their patent applications assessed for novelty, inventive step and industrial applicability before grant. According to Holland High Tech, the Cabinet approved these major changes to improve investment security and competitiveness.
• Thresholds are rising. Industry observers expect that the mandatory examination requirement will raise the bar for all new Dutch national filings. As ioplus has reported, the threshold for new patents will rise with mandatory examination, directly affecting how claims are drafted and defended.
• Direct PCT national entry becomes available. International applicants will be able to enter the Dutch national phase directly from a PCT application, bypassing the European Patent Office route where appropriate.
• Enforcement credibility improves. Examined patents carry greater presumptive validity in litigation, both before Dutch national courts and the Unified Patent Court (UPC), which is increasingly active in the Netherlands.
• Costs and timelines will shift. Budget for examination fees, more detailed claim drafting and potentially longer prosecution, but gain a stronger, more defensible right.

What you should do this month:

1. Audit your existing Dutch patent portfolio and pending applications to identify filings affected by transitional rules.
2. Reassess whether the national examined patent route or the EPO route best fits each invention in your pipeline.
3. Brief your patent counsel on sector-specific drafting adjustments, particularly around enablement data and claim scope for chemical and biotech inventions.

What Changed, The Dutch Patent Act 2026 Impact on the Netherlands Patent Landscape

Legislative Background

Until this reform, the Netherlands operated under the Rijksoctrooiwet 1995 (ROW 1995), which granted patents after a formal filing and a prior-art search report, but without substantive examination. The result was a “registration patent” system: patents were granted quickly and cheaply, but their validity was essentially untested until challenged in court. As EPC.nl has documented, plans for a New Netherlands Patent Act (Nieuwe Rijksoctrooiwet, or NROW) have been under development for several years, driven by concerns that unexamined patents offered insufficient legal certainty for innovators and investors alike.

The Cabinet’s decision, announced in early 2026, to proceed with major changes to the patent act was framed explicitly around investment security and the need to strengthen the Netherlands’ competitive position in innovation-intensive sectors. NL Times reported that the government is working on stricter patent rules in part to prevent the copying of Dutch innovations abroad. For chemical and biotech companies, which invest heavily in R&D and depend on robust patent protection, this policy shift is directly relevant.

Key Effective Dates and Transitional Rules

The legislative process for the NROW is underway, with the Cabinet having agreed to the reform package. Industry observers expect the following timeline based on government announcements and official business guidance published on Business.gov.nl:

Patentees with applications currently pending under the existing system should consult their advisors now to understand whether electing examination early may confer strategic advantages.

Examined Patent 2026 Explained, Mechanics, Thresholds and Options

Will the Netherlands introduce substantive (examined) patents in 2026? Yes. The Dutch patent reform reintroduces substantive examination as part of the national patent-granting process. Under the new regime, patent applications will be assessed for novelty, inventive step and sufficiency of disclosure before a patent is granted, aligning the Netherlands more closely with the examination standards applied by the European Patent Office.

How Substantive Examination in the Netherlands Will Operate

Under the current ROW 1995, the Netherlands Patent Office (Octrooicentrum Nederland) conducts a prior-art search and issues a search report, but does not refuse grant on substantive grounds. The examined patent 2026 model changes this fundamentally. The likely practical effect will be a multi-phase process:

• Filing and formalities check. The applicant files a national patent application (or enters the Dutch national phase via PCT). Formal requirements, description, claims, abstract, sequence listings where applicable, are verified.
• Prior-art search. A search report identifying relevant prior art is prepared, either by the Dutch patent office or by arrangement with the EPO (as is currently the case for Dutch search reports).
• Substantive examination. An examiner assesses the claims against novelty, inventive step and sufficiency of disclosure standards. The applicant may receive one or more office actions requiring claim amendments or additional evidence.
• Grant or refusal. Patents meeting all requirements are granted as “examined patents.” Applications that fail examination can be amended, divided or withdrawn.

Novelty and Inventiveness Thresholds

Early indications suggest that the mandatory patent examination thresholds will be aligned with European Patent Convention (EPC) standards, meaning novelty is assessed against the global state of the art, and inventive step is evaluated using the problem-solution approach familiar from EPO practice. For chemical and biotech patentees accustomed to EPO prosecution, this alignment is broadly positive: the same claim strategies and data packages that work at the EPO should be effective before the Dutch examiner.

However, the practical burden of persuading an examiner in a national office that may initially have less technical specialisation in niche biotech or chemical sub-fields could present challenges. Applicants should anticipate providing more detailed technical explanations in office action responses than they might at the EPO, where examiners in specific technology divisions are deeply embedded in the relevant prior art.

Procedural Timeline

Industry observers expect that the typical prosecution timeline for a Dutch examined patent will be longer than the current registration-only route (which can grant within approximately 12–18 months from filing). A reasonable estimate, based on analogous national examination systems, is 24–36 months from filing to grant for chemical and biotech applications, depending on complexity and the number of office actions required. This compares with the EPO’s average of 24–44 months for the same technology areas.

How the Dutch Patent Act 2026 Affects Chemical and Biotech Drafting

For patent strategy around chemical inventions and biotech patent prosecution in the Netherlands, the shift to examined patents introduces drafting considerations that were previously irrelevant in the national system. Under a registration regime, broadly drafted claims carry little immediate risk, they are granted regardless. Under examination, every element of claim scope must withstand scrutiny.

Chemical Inventions, Claim Examples and Drafting Tips

Chemical patents frequently rely on broad functional language (“a composition comprising a compound selected from the group…”) combined with Markush structures or ranges of numerical parameters. Under substantive examination, examiners will probe whether the full scope of such claims is supported by the experimental data in the description.

Key drafting adjustments include:

• Narrow the range, strengthen the data. If your application claims a pH range of 2–12 for an active formulation, but your examples only demonstrate efficacy at pH 4–7, expect an objection. Align claim scope with working examples.
• Provide comparative data. A claim directed to a “synergistic combination” of two active ingredients is far more defensible when accompanied by data showing the combination outperforms the individual components. As Bird & Bird has observed in the context of pharmaceutical and chemical patent strategy, a robust post-filing data approach can be decisive during examination.
• Use dependent claims strategically. Draft a layered claim set with progressively narrower fallback positions, so that if the broadest independent claim is rejected, you can seamlessly limit to a supported scope without losing protection.

Biotech Inventions, Enablement, Sequence Listings and Deposit Strategy

Biotech patent prosecution in the Netherlands under an examined system demands particular attention to enablement and sufficiency of disclosure. Examiners will assess whether a person skilled in the art can reproduce the invention across the full scope of the claims without undue burden. For biological sequences, protein variants and genetically engineered organisms, this means:

• File complete sequence listings. Sequence listings compliant with WIPO Standard ST.26 must accompany the application at filing. Omissions or errors are difficult to correct after the filing date.
• Consider Budapest Treaty deposits. For inventions involving biological material that cannot be adequately described in writing (novel microbial strains, plasmids, cell lines), deposit with a recognised International Depositary Authority and reference the deposit in the description.
• Limit functional claim language. A claim to “a polypeptide having at least 70% sequence identity to SEQ ID NO:1 and exhibiting enzymatic activity X” may be challenged if only a single variant has been tested. Provide sufficient examples spanning the claimed identity range, or narrow the range to match the data.

Evidence and Data Expectations During Examination

The table below illustrates common claim types used in chemical and biotech filings, the examination risks they attract, and practical mitigations:

These drafting disciplines apply regardless of whether you file nationally or via the EPO, but for patentees who previously used the Dutch national route precisely to avoid examination scrutiny, the Dutch patent reform requires a fundamental shift in approach. If you need guidance on protecting intellectual property across borders, sector-specific claim drafting is the critical starting point.

Prosecution Choices, Timelines and Costs, Practical Budgeting for Patent Costs in the Netherlands 2026

Chemical and biotech SMEs must now evaluate multiple prosecution routes, each with different patent costs in the Netherlands for 2026 and beyond. The following comparison table provides indicative estimates. Actual figures will depend on application complexity, number of claims and office actions, translation requirements and attorney fees.

Example Cost Model for a Chemical SME

A Netherlands-based chemical SME with three inventions per year might previously have spent roughly €12,000–€24,000 annually on Dutch national registrations. Under the examined patent system, the same portfolio could cost €24,000–€54,000, but with the significant advantage of holding patents that carry real presumptive validity. For context, the EPO route for three European patents (validated in the Netherlands, Germany and France) could run €45,000–€105,000. The national examined patent offers a middle path: stronger than a registration, cheaper than a full EPO prosecution, but limited to Dutch territorial coverage.

Tips to Reduce Examination Cost

• Draft right the first time. Invest in high-quality initial applications with robust data packages to reduce the number of office actions.
• Use EPO search reports. If you file at the EPO and then validate in the Netherlands, or if the Dutch office accepts EPO search reports, you avoid duplication of search costs.
• File divisional applications strategically. Rather than cramming multiple inventions into one application (risking unity objections), file focused applications that proceed cleanly through examination.
• Monitor fee schedules. The Netherlands Enterprise Agency (RVO) publishes official fee schedules on Business.gov.nl. Bookmark this resource and check for updates as the NROW is finalised.

Enforcement and Litigation Implications, Unified Patent Court Netherlands and National Courts

The enforcement landscape for chemical and biotech patents in the Netherlands is already complex, with parallel jurisdictions at Dutch national courts (particularly the District Court of The Hague, a specialist patent court) and the Unified Patent Court. The Dutch Patent Act 2026 impact on the Netherlands adds a new dimension: the examined patent as an enforcement tool.

UPC vs Dutch Courts, What Patentees Must Know

The Unified Patent Court Netherlands local division handles European patents with unitary effect and classic European patents (unless opted out). Dutch national patents, including newly examined ones under the NROW, remain outside UPC jurisdiction. This creates a strategic choice:

• Examined Dutch national patent: Enforced exclusively before Dutch courts. The advantage is territorial certainty, no risk of central revocation affecting protection in other countries. The examined status should strengthen validity arguments, reducing the risk of the patent being struck down in infringement proceedings.
• European patent (validated in NL): Enforceable before Dutch courts or the UPC (unless opted out). The UPC offers pan-European relief but carries the risk of pan-European revocation. As Hoyng Rokh Monegier’s analysis of recent UPC decisions illustrates, early case law is actively shaping the court’s approach to evidence, injunctive relief and claim construction.
• Dual strategy: Industry observers expect sophisticated patentees to maintain both a Dutch national examined patent and a European patent for the same invention family, using each in the jurisdiction that offers the most favourable tactical position. This “belt and braces” approach is particularly attractive for high-value chemical actives and blockbuster biotech products.

Evidence and Expert Witness Considerations in Chemistry and Biotech

Dutch courts have extensive experience with technically complex patent disputes, and the Chambers practice guide on patent litigation in the Netherlands confirms that expert evidence plays a central role. Under the examined patent regime, parties can point to the prosecution history, including office actions and applicant responses, as evidence of the patent’s scope and validity. For chemical and biotech cases, the quality of experimental data filed during prosecution directly influences enforcement strength. As a broader resource, the International Intellectual Property guide provides further context on how IP enforcement works across jurisdictions.

Practical Checklist and Decision Flowchart for Chemical and Biotech Patentees

The Dutch patent reform demands immediate action. Use the following checklist to prepare your organisation for the new examined patent system over the next 90 days:

1. Audit your Dutch patent portfolio. Identify all granted registrations and pending applications filed under the ROW 1995. Flag any that may benefit from voluntary examination under transitional rules.
2. Review pipeline inventions. For each invention in development, determine whether a Dutch national examined patent, an EPO filing, a PCT-to-Dutch-national entry, or a combination best serves your commercial objectives.
3. Assess claim-drafting readiness. Review draft patent applications for enablement and support issues. Chemical claims should be backed by representative experimental data; biotech claims need compliant sequence listings and, where necessary, biological deposits.
4. Update your IP budget. Reallocate prosecution budgets to account for examination fees, additional attorney time for office action responses, and potential divisional filings.
5. Brief external patent counsel. Provide your patent attorney with a prioritised list of applications and ask for a strategic recommendation on route selection (national vs EPO vs PCT) for each family.
6. Check transitional provisions. Monitor official government publications on Business.gov.nl and the Netherlands Patent Office website for finalised transitional rules affecting pending applications.
7. Consider UPC opt-out decisions. For European patents validated in the Netherlands, evaluate whether opting out of UPC jurisdiction (or revoking an existing opt-out) makes strategic sense in light of your new national examined patent.
8. Prepare data packages for key applications. If you anticipate filing national applications in the chemical or biotech space, start compiling experimental data now. Robust data reduces prosecution time and cost.
9. Align with commercial strategy. Ensure that patent strategy decisions reflect commercial priorities, territorial coverage, licensing plans, freedom-to-operate needs and litigation risk appetite.
10. Schedule a portfolio review meeting. Bring together R&D leads, in-house counsel and external patent advisors within the next 30 days to agree on a unified response to the Dutch patent reform. Browse the Global Law Experts lawyer directory to identify qualified specialists in Dutch intellectual property law.

Decision flowchart, choosing your route:

• Need protection only in the Netherlands? → File a Dutch national examined patent under the NROW. Fastest, cheapest single-country route with strong enforcement value.
• Need protection in multiple European countries? → File at the EPO (or use PCT → EPO regional phase). Validate in the Netherlands and other target countries. Consider UPC unitary patent for broadest reach.
• Need both speed and breadth? → File a Dutch national application for early territorial protection and a parallel EPO/PCT application for broader coverage. This dual-track strategy is common for high-value inventions in the chemical and biotech sectors.
• Entering from a PCT application? → Evaluate direct Dutch national-phase entry (newly available under the NROW) versus EPO regional-phase entry based on territorial coverage needs, cost and prosecution timeline.

Conclusion, Dutch Patent Act 2026 Impact: Recommended Next Steps

The Dutch Patent Act 2026 impact on the Netherlands patent system is transformative for chemical and biotech patentees. The reintroduction of substantive examination creates stronger, more defensible rights, but demands higher-quality applications, more sophisticated prosecution strategies and larger budgets. For innovators willing to adapt, the examined patent 2026 regime offers a significant competitive advantage: patents that carry real weight in licensing negotiations, investment due diligence and courtroom enforcement.

The practical implications vary by organisation size. Startups should focus on one or two high-quality examined patent applications covering core technology, rather than spreading resources thin. Mid-sized companies benefit most from the dual-track national-plus-EPO strategy described above. Large enterprises should conduct a comprehensive portfolio audit and consider the enforcement interplay between Dutch national courts and the Unified Patent Court Netherlands division.

Whatever your scale, the time to act is now, before the NROW enters into force. Review your pipeline, strengthen your data packages, and ensure your patent strategy for chemical inventions and biotech innovations reflects the new reality. For guidance tailored to the Netherlands, consult a qualified European patent attorney experienced in the chemical and biotech sectors. Additional resources are available in the International Intellectual Property guide and through the lawyer directory on Global Law Experts.

Sources

1. ioplus, Threshold for new patents will rise with mandatory examination
2. Holland High Tech, Cabinet makes major changes to patent act
3. Business.gov.nl, Changes in law and regulations, 1st quarter 2026
4. EPC.nl, Er komt een nieuwe Rijksoctrooiwet (New Netherlands Patent Act)
5. European Patent Office, Search and Examination Matters 2026
6. Chambers Practice Guides, Patent Litigation 2026: Netherlands
7. NL Times, Dutch govt working on stricter patent rules
8. Bird & Bird, Post-filing data strategy in pharmaceuticals and chemical fields
9. Hoyng Rokh Monegier, UPC Unfiltered: UPC decisions, Week 10 2026
10. RVO, Patents: system and fees in the Netherlands